At a glance
ClinicalIndex Comparison Record- ✓Aged ≥18 years with AML in first CR or CRi
- ✓Not immediate candidates for allogeneic stem cell transplant
- ✓Received intensive cytarabine-based induction therapy with ≥1 consolidation cycle, within 2 months of last consolidation (or any time if MRD+)
- ✓Received lower-intensity LDAC or HMA therapy with ≥2 cycles to achieve CR/CRi (or any time if MRD+)
- ✕Diagnosis of acute promyelocytic leukemia (APL) or AML-M3 by morphology, immunophenotype, molecular, or cytogenetics
- ✕AML with t(15;17) or APL variant
- ✕t(9;22) unless unable/unwilling to receive tyrosine kinase inhibitor therapy
- ✕Uncontrolled intercurrent illness including active infection, symptomatic heart failure, unstable angina, arrhythmia, or psychiatric illness
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Decitabine-Based Maintenance Therapy in Patients With AML in Remission
In Brief
A Phase 1 clinical trial evaluating Decitabine and Cedazuridine, Enasidenib, and 3 other interventions for Acute Myeloid Leukemia. Currently recruiting, targeting 125 participants across 1 site.
Detailed Summary
This phase Ib trial is to find out the side effects and possible benefits of decitabine alone or given together with venetoclax, gilteritinib, enasidenib, or ivosidenib in treating patients with acute myeloid leukemia that is under control (remission). Chemotherapy drugs, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells by blocking a protein called Bcl-2 needed for cell growth. Gilteritinib, enasidenib, and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving decitabine alone or together with venetoclax, gilteritinib, enasidenib, or ivosidenib may help to control the disease.
Study Details
Timeline
Interventions
Given PO
Given PO
Given PO
Given PO
Given PO